Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer

PARP inhibitors target BRCA mutations and defective homologous recombination repair (HRR) for the treatment of epithelial ovarian cancer (EOC). However, the treatment of HRR-proficient EOC with PARP inhibitors remains challenging. The objective of this study was to determine whether the combination...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:PLoS One
Asıl Yazarlar: Lin, Z. Ping, Zhu, Yong-Lian, Lo, Ying-Chun, Moscarelli, Jake, Xiong, Amy, Korayem, Yasmin, Huang, Pamela H., Giri, Smith, LoRusso, Patricia, Ratner, Elena S.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Public Library of Science 2018
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6239325/
https://ncbi.nlm.nih.gov/pubmed/30444904
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0207399
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller